Mevastatin

Mevastatin

SCHEMBL1116

CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 7/20 1.00
HMGCR P04035 6/20 1.00
LMNA P02545 5/20 1.00
TSHR P16473 5/20 1.00
SMN1; SMN2 Q16637 4/20 1.00
HIF1A Q16665 4/20 1.00
MEN1 O00255 3/20 1.00
KMT2A Q03164 3/20 1.00
ABCB11 O95342 3/20 1.00
ALDH1A1 P00352 2/20 1.00
CYP1A2 P05177 2/20 1.00
MAPK1 P28482 1/20 1.00
MTOR P42345 1/20 1.00
HTT P42858 1/20 1.00
NPSR1 Q6W5P4 1/20 1.00
GMNN O75496 1/20 1.00
TP53 P04637 1/20 1.00
CYP2D6 P10635 1/20 1.00
NFKB1 P19838 1/20 1.00
BLM P54132 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Mevastatin SCHEMBL14545225 1.00 CYP3A4 (1.00) CYP3A4HMGCRLMNATSHRSMN1; SMN2
Mevastatin SCHEMBL15976637 1.00 CYP3A4 (1.00) CYP3A4HMGCRLMNATSHRSMN1; SMN2
Mevastatin SCHEMBL14307237 1.00 CYP3A4 (1.00) CYP3A4HMGCRLMNATSHRSMN1; SMN2
Mevastatin SCHEMBL4544785 1.00 CYP3A4 (1.00) CYP3A4HMGCRLMNATSHRSMN1; SMN2
Mevastatin SCHEMBL23936978 1.00 CYP3A4 (1.00) CYP3A4HMGCRLMNATSHRSMN1; SMN2
Mevastatin SCHEMBL7721400 1.00 CYP3A4 (1.00) CYP3A4HMGCRLMNATSHRSMN1; SMN2
Mevastatin SCHEMBL23636208 1.00 CYP3A4 (1.00) CYP3A4HMGCRLMNATSHRSMN1; SMN2
Mevastatin SCHEMBL21340588 1.00 CYP3A4 (1.00) CYP3A4HMGCRLMNATSHRSMN1; SMN2
Mevastatin SCHEMBL21340571 1.00 CYP3A4 (1.00) CYP3A4HMGCRLMNATSHRSMN1; SMN2
Mevastatin SCHEMBL21340628 1.00 CYP3A4 (1.00) CYP3A4HMGCRLMNATSHRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 29588 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4051153-B1 COMPACT LASER-STEERING END EFFECTOR HARVARD COLLEGE (US) 2026-05-27 EP claimed
WO-2026104329-A1 SYSTEM AND METHOD FOR DETECTING OPTICAL SIGNALS OF A TEST OBJECT THAT IS MOVED RELATIVE TO A TARGET Deutsches Zentrum für Luft- und Raumfahrt e.V. (DE) 2026-05-21 WO claimed
EP-3729084-B1 IMMUNE CELL ORGANOID CO-CULTURES KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN (NL) 2026-05-20 EP claimed
EP-4745160-A1 METHOD FOR TREATING OR PREVENTING CHOLESTEROL-RELATED DISEASES USING PCSK9 INHIBITOR Salubris (Chengdu) Biotech Co., Ltd. (CN) 2026-05-20 EP claimed
EP-4093327-B1 ENDOPROSTHESES WITH INTERLOCKING STENTS HAVING VARYING STIFFNESS GORE & ASS (US) 2026-05-06 EP claimed
EP-4255391-B1 LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION METRIOPHARM AG (CH) 2026-05-06 EP claimed
EP-3681297-B1 PROCESS OF MAKING CURED MEAT PRODUCTS BASED ON NON-MINCED COOKED MEAT AND NON-MINCED COOKED MEAT MADE WITH SUCH PROCESS ROVAGNATI S P A (IT) 2026-05-06 EP claimed
EP-4731433-A1 SYSTEM AND METHOD FOR PRODUCING PAPER STICKS Setter Holding GmbH (DE) 2026-04-29 EP claimed
EP-4248976-B1 ANTIGEN BINDING PROTEINS TO PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9) AMGEN INC (US) 2026-04-22 EP claimed
EP-3971084-B1 AÉRONEF MULTI-ROTOR PLIABLE SZ DJI TECHNOLOGY CO LTD (CN) 2026-04-22 EP claimed
US-5130333-A Mevastatin, lovastatin, pravastatin or velostatin for diabetes and cholesterol reduction E. R. SQUIBB & SONS, INC. (US) 1992-07-14 US claimed
EP-0482498-A2 Method for preventing diabetic complications employing a cholesterol lowering drug alone or in combination with an ace inhibitor E.R. SQUIBB & SONS, INC. (US) 1992-04-29 EP claimed
EP-0461548-A2 Method for preventing a second heart attack employing and HMG CoA reductase inhibitor E.R. SQUIBB & SONS, INC. (US) 1991-12-18 EP claimed
EP-0457514-A1 Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor E.R. SQUIBB & SONS, INC. (US) 1991-11-21 EP claimed
EP-0429306-A2 Data compaction system International Business Machines Corporation (US) 1991-05-29 EP claimed
EP-0401705-A2 Use of an HMG CoA reductase inhibitor and/or a squalene synthetase inhibitor for treating peripheral atherosclerotic disease E.R. Squibb & Sons, Inc. (US) 1990-12-12 EP claimed
US-4950775-A REACTING ALDEHYDE WITH KETOPHOSPHONATE SYNTHON UNIVERSITY OF CALIFORNIA (US) 1990-08-21 US claimed
EP-0373931-A2 Monoesters of arylacetic acid, their production and use SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. (JP) 1990-06-20 EP claimed
EP-0373507-A1 Combination of an HMG CoA reductase inhibitor and other type of serum cholesterol reducing agent and method for lowering serum cholesterol using such combination E.R. SQUIBB & SONS, INC. (US) 1990-06-20 EP claimed
EP-0010299-A1 Pharmaceutical composition useful for the treatment of hypercholesteremia MERCK & CO. INC. (US) 1980-04-30 EP claimed